Keokia Leora Mendiola, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 111 San Carlos Lane, Asan, GU 96922 Phone: 671-482-4845 |
Nicole L.p Duenas Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5500 |
Regina Day, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5500 |
Rowena Quinto Dimla Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 809 Chalan Pasaheru Unit 2, Tamuning, GU 96913 Phone: 671-647-5355 |
Mr. Daniel B. Domaoal, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 396 Chalan San Antonio, Bri Bldg, Suite 101, Tamuning, GU 96913 Phone: 671-685-1952 |
Mrs. Sibyl Dgg Crisostomo, MS Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 770 Toto Canada Road, Toto, GU 96931 Phone: 671-477-7773 Fax: 671-477-7773 |
Briana Schell, M.S. ED, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 245 La Cuesta Cir, Yona, GU 96915 Phone: 671-788-8971 |
News Archive
It was painful to watch Minnesota's stellar health care reputation and its Human Services commissioner, Lucinda Jesson, get pummeled on Wednesday at a congressional hearing on Medicaid oversight.
A joint study by researchers from Nanyang Technological University, Singapore and clinicians at Tan Tock Seng Hospital has yielded insights into how doctors can better communicate the value of clinical investigations to patients.
The National Rheumatoid Arthritis Society in collaboration with 2020health, a leading health social enterprise think tank, today announces the results from Invisible Disease: RA and Chronic Fatigue 2014, a survey of 1,954 people with Rheumatoid Arthritis (RA), to assess the impact of chronic fatigue on their capability for work, emotional and mental health as well as the overall experience of chronic fatigue caused by their RA.
GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.
› Verified 6 days ago